Synergy Rx Review: $275 NAD+, and a Terms Clause That Unbinds It

The one-sentence version

Synergy Rx does the rare thing on this board: it prints four longevity prices on its own homepage, month-to-month, with no prepay term standing between you and them — NAD+, sermorelin and glutathione injections at $275 a month each and B-12 methylcobalamin at $109. It names four dispensing pharmacies with phone numbers, names two prescribing physicians with NPI numbers, and publishes unlimited appointments and 24/7 support as part of the plan. Then its own documents undercut the thing it does best: the published prices are not binding, the "Money Back Guarantee" on one page is contradicted by "all sales are final" on another, and it will not tell you which states it serves. It grades A, 11 points out of 14 — the bottom of the A band, with two of the three points it drops taken for disclaiming its own prices. The grade is computed from published terms alone and is blind to who pays us; Synergy Rx is a paid partner here.

What it is, and what it sells

The operating entity is SynergyRx, described in its own Terms as "a Delaware corporation located at 5830 E 2nd St, Ste 7000 #2603, Casper, WY 82609." The commerce platform is CareGLP, which SynergyRx owns, and medical services are delivered by Usable Health, PC. That last arrangement matters: the company you buy from and the practice that prescribes to you are two different legal entities, which is normal in this category and worth knowing anyway.

The Longevity tab on the homepage is the whole of what this board ranks, and it is short and legible:

Beside it sit hair (four products at $109), ED tablets and sublingual strips (all $109), six compounded skin creams at $119, and the GLP-1 line — compounded semaglutide at $199/mo, compounded tirzepatide at $349/mo, sublingual ODT versions at $299 and $399, and brand Ozempic at $499 with Wegovy and Mounjaro at $947.

What it does not sell: no other growth-hormone peptides, no methylene blue, no TRT or HRT, no BPC-157 or TB-500, no supplements.

The pricing, and the clause that hangs over it

Start with what is genuinely good, because it is unusual. Those four figures are rendered in the homepage's own HTML. There is no quiz gate, no "get your personalised quote", no membership wrapped around them. Every one is a month-to-month rate. And Synergy's multi-month bundles are, remarkably, worse value than paying monthly — the three-month semaglutide bundle costs $748, which is $249 a month against $199 month-to-month, and the three-month tirzepatide bundle is $356 a month against $349. That is the inverse of this vertical's usual trap, where the advertised number turns out to be a twelve-month prepay. Here the cheapest rung is the shortest commitment, and nothing needs unpicking to see it.

Now the clause. Section XII of the Terms, verbatim:

> "Kindly be advised that the final charge to your credit card may fluctuate contingent upon the prescribed medication and the chosen pharmacy for order fulfillment. Should any variance arise in the charge, a dedicated member of our support team will expeditiously communicate the details to you."

Read that beside the product-level fineprint and it stops being boilerplate. Glutathione, B-12 and the skin creams are not shipped to Alabama, Arkansas, Alaska, Connecticut, Indiana, Kentucky, Louisiana, Michigan, Minnesota, Vermont or Wisconsin. NAD+ is served in those eleven states — but by secondary pharmacies, and the catalogue's own words are that cost may vary. Sermorelin and PT-141 route through a secondary pharmacy in Alabama on the same terms. So the company has told you twice, in two places, that $275 is an expectation rather than a quotation.

And the homepage says it too, one screen below the prices. Synergy's own FAQ answers "How much does the program cost?" with: "Program pricing varies depending on your treatment plan, medication type, and whether you choose compounded or brand-name medications. Transparent pricing is provided after your consultation." That is on the same page as the $275 tiles. The number and the disclaimer of the number are visible without scrolling twice.

What that costs, and why the rule is not aimed at Synergy. Our rubric now scores price transparency on three rungs rather than two: four points for an all-in figure the provider stands behind, two for one it publishes and then disclaims, and zero where no such figure exists before you commit. Synergy lands on the middle rung, which is the honest description of what it does — it publishes real, ungated, month-to-month numbers, and it also tells you they may not be what you are charged. That is genuinely better than the rows publishing nothing, and genuinely worse than a price that binds.

Worth stating plainly, because the rule arrived from reading this company's terms: it was applied to every row on the board that publishes a price — twenty of them, swept page by page on the same day — and three came back positive. A rule written for one row and applied to one row is not a rule. Get the number confirmed in writing before you accept a prescription, and confirm it again if you live in one of the eleven states.

One more thing that is not a price. A "$100 welcome credit… no code needed" and a "2026 Promo Applied!" banner run site-wide with no published terms attached to either. Treat both as marketing furniture until somebody quotes you a figure.

Who prescribes, who dispenses, and what is missing

Four pharmacies, named, with phone numbers. Synergy's own homepage FAQ lists Belmar Pharmacy, Strive Pharmacy, Epiq Scripts and Casa Pharma Rx, each with a telephone number and a website. In a category whose standard practice is to say "a licensed US pharmacy" and stop, that is real disclosure. What it never does is classify them: the strings "503A" and "503B" appear nowhere on the site, so you know who fills your prescription but not under which regime. That is the middle rung of our pharmacy ladder, and it is what Synergy earns — one point of two. Found Health states the standard and names nobody; Synergy names four and states no standard. Neither is complete.

Two physicians, named, with NPI numbers. The clinical group is Lion MD, led by Dr. Ana Lisa Carr, MD (NPI 1689841744) and Dr. Kelly Tenbrink, MD (NPI 1346482684) — both verifiable as active in the NPPES registry, Carr in family medicine and Tenbrink in emergency medicine. Volunteering a checkable identifier is rare and worth crediting. The gap is the same one every asynchronous practice has: on an intake reviewed remotely, the clinician who writes your prescription is very probably not one of the two people you were shown.

Support is published as included, and specifically: "Unlimited 24/7 Support Included… With unlimited appointments, messaging and support", with the homepage's own process adding that "Ongoing support is provided through monthly check-ins and messaging access." That is a statement about what the price buys, not a customer-service phone number, which is the distinction this factor turns on.

And then the states. Synergy publishes no list of the states it serves. Its Terms say the service is "available to individuals located in certain states. To see the list of current states, please contact customer service." Any claim you read elsewhere that Synergy covers all fifty is unsupported by anything the company currently publishes. Our rubric has no factor for state coverage — which is a limit of the rubric, and the honest thing is to say so here rather than invent a factor after seeing which row it would hit.

The self-contradictions

"Money Back Guarantee" versus "all sales are final." The /about page advertises a Money Back Guarantee among its trust badges. Section XII of the Terms says: "If you receive a medical consultation, medical consult fees are not subject to or eligible for a refund. We cannot accept returns of prescription products for reuse or resale, and all sales are final." Both are live on the same site today. Only one of them is the contract.

The PT-141 description is the sermorelin copy on the wrong molecule. Synergy's PT-141 product page credits the drug with raising the body's own growth-hormone production and the downstream effects that follow from that. PT-141 (bremelanotide) is a melanocortin receptor agonist used for sexual dysfunction. It does not do that. We are not reproducing the sentence, because it is wrong and it travels — the same copy is byte-identical across the CareValidate-platform brands, and errors in shared boilerplate get quoted onward by people who assume a product page describes the product. Take it as a warning about the whole product-copy layer: treat any clinical claim on these pages as unchecked, and read what the peptide evidence actually supports instead.

"Join 50,000+ SynergyRx patients" has no published basis. And no dose strengths are given for NAD+ or sermorelin anywhere, so whether $275 holds as a dose rises cannot be established before you pay — its sibling brand Care Bare Rx, running on the same platform, publishes the dose ladder Synergy strips out.

The evidence behind what it sells

This board grades providers, not molecules. But $275 a month is $3,300 a year, and the state of the evidence belongs in that decision.

The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials. Oral precursors do reliably raise blood NAD+² — that part holds — but effects on functional, metabolic and vascular outcomes were "heterogeneous and often null or endpoint-specific," and clinical effectiveness for anti-aging or wellness "remains inconclusive"³. On the route Synergy actually sells, the same review is blunter: no eligible outcomes trial has evaluated injected NAD+ for these indications at all³. A 2025 meta-analysis in adults averaging over 60 found NAD+ precursors did not improve muscle index, grip strength, gait speed or chair-stand time⁴.

Sermorelin is a growth-hormone-releasing analogue, and the honest summary of GH augmentation in healthy older adults is the 2007 Annals systematic review: small changes in body composition, no demonstrated functional benefit, and a higher rate of adverse events⁵. Glutathione by injection has less human outcome evidence still.

None of that is a mark against Synergy in particular — it is the state of the category, and the company markets within its normal register. Compounded NAD+, sermorelin and glutathione are not FDA-approved, and FDA's own position is that compounded drugs are not FDA-approved and the agency does not verify their safety, effectiveness or quality before they are marketed¹.

Where it's weak, and who should skip it

Skip it if you need to know before you start that your state is covered, because Synergy will not tell you without a phone call. Skip it if a Terms clause saying your charge may differ from the advertised price is a risk you will not take on a recurring bill. Skip it if you need to know what dose $275 buys, or what a higher dose costs, because neither is published. And skip it if the refund position matters to you: on Synergy's own Terms, consult fees are non-refundable and all sales are final, whatever the badge on /about says.

Buy it if a published, ungated, genuinely month-to-month price is the thing you have been unable to find elsewhere — because most of this board cannot manage it — and if you are willing to do the one piece of work this provider leaves you: get the state, the dose and the final charge confirmed in writing before you accept anything.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Synergy takes two of four for price transparency — the middle rung, because the figures are published, ungated and month-to-month and its own documents then disclaim them; four for its longevity line, because NAD+, sermorelin and glutathione injections are exactly what this board exists to rank; two for clinical oversight, because the consultation sits inside the plan and unlimited appointments are stated as included; and two for support, on the published 24/7 messaging and monthly check-ins. It drops one point on pharmacy, because it names four facilities and classifies none. Eleven out of fourteen: an A, at the very bottom of the band — one point above a B.

Which is the uncomfortable part, and worth stating plainly: the rubric measures what a provider publishes about its price, its line, its oversight, its pharmacy and its support — and on all five Synergy does well. It has no factor for a missing state list, for a guarantee its Terms contradict, or for a product description attached to the wrong molecule. Those are real, they are why this review is as long as it is, and they are the reason to read the whole page rather than the letter. The full graded field is at our provider rankings, the scoring is set out in how we grade, and what this category costs generally is in longevity clinic cost.